Gambaran Kejadian Ikutan Pasca Imunisasi (KIPI) Covid-19 pada Individu dengan Komorbid Diabetes Mellitus
Sari
Patients with diabetes mellitus have a fairly high risk of worsening their condition when experiencing Covid-19. This is because individuals are more susceptible to exposure to streptococcal infections, which cause pneumonia, which is a serious complication of respiratory tract problems when exposed to Covid-19. To reduce the impact of these complications, a strategy is needed to increase the immunity of individuals with comorbid diabetes mellitus through the Covid-19 vaccination. The implementation of this vaccination can give a different response to each individual recipient and depends on many factors, including the presence of a previous disease such as diabetes mellitus. The purpose of this study was to get an overview of Covid-19 post-immunization follow-up events (AEFI) in individuals with comorbid diabetes mellitus. This research method is cross-sectional with a purposive sampling technique. The study was conducted on 299 adult respondents who had comorbid diabetes mellitus and received the Covid-19 vaccination. The results of the study obtained data showed that as many as 65 (11,2%) respondents reported not having AEFI symptoms; local symptoms experienced by respondents were swelling (n. 3; 0,5%) and redness at the injection site (n. 1; 0,2%); systemic symptoms experienced by respondents were cramps or muscle pain (n. 104; 17,9%); dizziness (n. 100; 17,2%); fever (n. 99; 17,1%); and drowsiness (n. 93; 16,0%). The degree of AEFI in respondents who had mild symptoms was 93 (16,04%), and moderate symptoms were 422 (72,76%). None of the respondents experienced severe symptoms. Based on these results, it was concluded that the most frequent symptoms were moderate symptoms and systemic symptoms. Even though no severe symptoms are experienced, individual preparation is needed before getting the vaccine to reduce the symptoms of AEFI.
Kata Kunci
Teks Lengkap:
PDFReferensi
Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131–4.
Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama. 2020;323(13):1239–42.
Bloomgarden ZT. Diabetes and COVID‐19. J Diabetes. 2020;12(4):347–8.
Wang Y, Duan L, Li M, Wang J, Yang J, Song C, et al. COVID-19 vaccine hesitancy and associated factors among diabetes patients: a cross-sectional survey in Changzhi, Shanxi, China. Vaccines. 2022;10(1):129.
Tiana E, Amalia N. Gambaran Persepsi Masyarakat Terhadap Vaksin Covid-19. Borneo Student Res. 2021;3(1):526–31.
Menteri Kesehatan Republik. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/4638/2021 Tentang Petunjuk Teknis Pelaksanaan Vaksinasi Dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (Covid-19). 2021;
Koesnoe S. Teknis Pelaksanaan Vaksin Covid dan Antisipasi KIPI. SatGas Imunisasi Dewasa PB PAPDI PP Perhimpun Alergi Imunol Jakarta Perhimpun Dr Spes Penyakit Dalam Indones Cab Bogor. 2021;
Lidiana EH, Mustikasari H, Pradana KA, Permatasari A. Gambaran karakteristik kejadian ikutan pasca vaksinasi Covid-19 pada tenaga kesehatan alumni Universitas ‘Aisyiyah Surakarta. J Ilm Kesehat. 2021;11(1):11–7.
Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr Clin Res Rev. 2021;15(5):102207.
Dewi SM. Faktor Risiko Terjadinya Kejadian Ikutan Pasca Imunisasi (KIPI) pada Penerima Vaksin Covid-19 Dosis Pertama di Kecamatan Cimanggis Kota Depok Tahun 2021. Universitas Pembangunan Nasional Veteran Jakarta; 2022.
Heald AH, Stedman M, Horne L, Rea R, Whyte M, Gibson JM, et al. The change in glycaemic control immediately after COVID‐19 vaccination in people with type 1 diabetes. Diabet Med. 2022;39(4):e14774.
Ganakumar V, Jethwani P, Roy A, Shukla R, Mittal M, Garg MK. Diabetic ketoacidosis (DKA) in type 1 diabetes mellitus (T1DM) temporally related to COVID-19 vaccination. Diabetes Metab Syndr Clin Res Rev. 2022;16(1):102371.
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes–global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107.
Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):1–11.
Delfina S, Carolita I, Habsah S. Analisis Determinan Faktor Risiko Kejadian Diabetes Mellitus Tipe 2 Pada Usia Produktif. J Kesehat Tambusai. 2021;2(4):141–51.
Sinclair AJ, Abdelhafiz AH. Age, frailty and diabetes–triple jeopardy for vulnerability to COVID-19 infection. EClinicalMedicine. 2020;22.
Fauzia NS. Faktor Risiko Terjadinya Coronavirus Disease 2019 Pada Pasien Dengan Komorbid Diabetes Melitus. Arter J Ilmu Kesehat. 2021;2(4):105–12.
Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr Clin Res Rev. 2021;15(2):505–8.
Safira M, Peranginangin M, Saputri GAR. Evaluasi Monitoring Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Covid-19 (Coronavac) pada Tenaga Kesehatan di Rumah Sakit Imanuel Bandar Lampung. J Mandala Pharmacon Indones. 2021;7(2):251–62.
Piccini B, Pessina B, Pezzoli F, Casalini E, Toni S. COVID‐19 vaccination in adolescents and young adults with type 1 diabetes: Glycemic control and side effects. Pediatr Diabetes. 2022;23(4):469–72.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.
Abbas S, Abbas B, Amir S, Wajahat M. Evaluation of adverse effects with COVID-19 vaccination in Pakistan. Pakistan J Med Sci. 2021;37(7):1959.
Pieralice S, D’Onofrio L, Pozzilli P, Buzzetti R. Third dose of COVID‐19 vaccine in diabetes: Relevance of good metabolic control to improve its efficacy. Diabetes Metab Res Rev. 2022;
Khan F, Khan MT, Zaman S, Mujtaba S, Batool A, Ghanghro Z, et al. Side effects of COVID-19 vaccines among diabetic subjects and healthy individuals. Cureus. 2023;15(3).
DOI: https://doi.org/10.33992/jgk.v16i1.2504
##submission.license.cc.by-nc-sa4.footer##
Jurnal Gema Keperawatan diindeks oleh :
Jurnal Gema Keperawatan berada dibawah lisensi Creative Commons Attribution-ShareAlike 4.0 International License.
View My Stats